^
    1d
    FIL_LymDeCo: Neurocognitive Assessment in Long-Term Survivors of Lymphoma (clinicaltrials.gov)
    P=N/A, N=100, Not yet recruiting, Fondazione Italiana Linfomi - ETS
    New trial
    1d
    A Feasibility Trial of Tazemetostat Plus CAR T Cell Therapy in B-cell Lymphomas (clinicaltrials.gov)
    P1, N=15, Active, not recruiting, Weill Medical College of Cornell University | Recruiting --> Active, not recruiting | Trial primary completion date: Sep 2026 --> May 2026
    Enrollment closed • Trial primary completion date
    |
    Tazverik (tazemetostat)
    1d
    D7400C00006: A Study of AZD0486 in Subjects With B-Cell Non-Hodgkin Lymphoma (clinicaltrials.gov)
    P1, N=226, Active, not recruiting, AstraZeneca | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    CD19 positive
    |
    surovatamig (AZD0486)
    1d
    Mogamulizumab for adult T-cell leukemia/lymphoma: a literature review. (PubMed, Transl Cancer Res)
    However, clinicians should be aware of potential adverse effects, including infusion-related reactions, rashes, infections, as well as the increased risk of steroids-refractory acute graft-versus-host disease (GVHD), when mogamulizumab is used before allogeneic stem cell transplant (allo-SCT). Larger, prospective, randomized trials are needed to validate the current findings.
    Review • Journal • IO biomarker
    |
    CCR4 (C-C Motif Chemokine Receptor 4)
    |
    Poteligeo (mogamulizumab-kpkc)
    1d
    Application of Hi-C sequencing to detect oncogene rearrangements for diagnosis and treatment of large B-cell lymphoma. (PubMed, Blood Adv)
    In conclusion, Hi-C sequencing detects gene rearrangements crucial for diagnosis in an unbiased and molecular manner and showed high sensitivity and specificity in our study. These advantages of Hi-C sequencing offer help to improve the workflow of clinical pathology laboratories, diagnostic precision, and treatment of large B-cell lymphoma.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • MYC (V-myc avian myelocytomatosis viral oncogene homolog) • NTRK1 (Neurotrophic tyrosine kinase, receptor, type 1) • BCL2 (B-cell CLL/lymphoma 2) • CCND1 (Cyclin D1) • BCL6 (B-cell CLL/lymphoma 6) • FANCE (FA Complementation Group E)
    1d
    Loss of HTLV-1-specific CD8+ T-cell immunity in virus carriers predisposed to adult T-cell leukemia/lymphoma. (PubMed, Blood Neoplasia)
    This is the first report of HTLV-1-specific immune dysregulation in the premalignant stage of ATL. Low frequencies of HTLV-1-specific CD8 + T cells may contribute to ATL development and may be a novel therapeutic target for ATL prevention.
    Journal
    |
    CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma)
    1d
    19-C-0116: Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell Lymphoma (clinicaltrials.gov)
    P2, N=132, Recruiting, National Cancer Institute (NCI) | Trial completion date: Mar 2030 --> Mar 2031 | Trial primary completion date: May 2026 --> May 2027
    Trial completion date • Trial primary completion date
    |
    ALK (Anaplastic lymphoma kinase) • BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6)
    |
    Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • Calquence (acalabrutinib)
    1d
    The CARDIOPROTECT Trial (clinicaltrials.gov)
    P2, N=60, Not yet recruiting, Beth Israel Deaconess Medical Center
    New P2 trial
    |
    Rituxan (rituximab) • cyclophosphamide • pegylated liposomal doxorubicin • vincristine • prednisone • Truxima (rituximab-abbs) • Myocet (non-pegylated liposomal doxorubicin) • Polivy (polatuzumab vedotin-piiq) • dexrazoxane
    1d
    CART-Omic: Radiomics and Metabolomics in the Follow-up of CAR T-cells for Refractory or Relapsed Non-Hodgkin's Lymphoma (clinicaltrials.gov)
    P=N/A, N=20, Completed, Centre Hospitalier Universitaire de Nice | Trial primary completion date: Feb 2025 --> Dec 2025 | Recruiting --> Completed
    Trial completion • Trial primary completion date
    2d
    Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL (clinicaltrials.gov)
    P3, N=466, Recruiting, Alliance for Clinical Trials in Oncology | Not yet recruiting --> Recruiting | Initiation date: Jan 2026 --> Apr 2026
    Enrollment open • Trial initiation date
    |
    CD20 (Membrane Spanning 4-Domains A1) • CD5 (CD5 Molecule) • FCER2 (Fc Fragment Of IgE Receptor II)
    |
    Chr t(11;14)
    |
    clonoSEQ®
    |
    Brukinsa (zanubrutinib) • Beqalzi (sonrotoclax)
    2d
    CRIMSON-NE: Cell Therapy for High Risk T-Cell Malignancies Using CD7-Specific CAR Expressed On Autologous T Cells (clinicaltrials.gov)
    P1, N=45, Active, not recruiting, Baylor College of Medicine | Recruiting --> Active, not recruiting | N=27 --> 45 | Trial completion date: May 2040 --> Mar 2041
    Enrollment closed • Enrollment change • Trial completion date
    |
    CD7 (CD7 Molecule)
    |
    cyclophosphamide